GeneMatrix Inc - Asset Resilience Ratio

Latest as of September 2025: 41.52%

GeneMatrix Inc (109820) has an Asset Resilience Ratio of 41.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩11.64 Billion
≈ $7.89 Million USD Cash + Short-term Investments

Total Assets

₩28.03 Billion
≈ $19.00 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2024)

This chart shows how GeneMatrix Inc's Asset Resilience Ratio has changed over time. Check GeneMatrix Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down GeneMatrix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is GeneMatrix Inc worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩11.64 Billion 41.52%
Total Liquid Assets ₩11.64 Billion 41.52%

Asset Resilience Insights

  • Very High Liquidity: GeneMatrix Inc maintains exceptional liquid asset reserves at 41.52% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

GeneMatrix Inc Industry Peers by Asset Resilience Ratio

Compare GeneMatrix Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Chemclin Diagnostics Co. Ltd. A
SHG:688468
Diagnostics & Research 15.34%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%
Bcal Diagnostics Ltd
AU:BDX
Diagnostics & Research 0.00%
Check Cap Ltd
NASDAQ:CHEK
Diagnostics & Research 70.29%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Cryosite Ltd
AU:CTE
Diagnostics & Research 5.65%

Annual Asset Resilience Ratio for GeneMatrix Inc (2011–2024)

The table below shows the annual Asset Resilience Ratio data for GeneMatrix Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 6.41% ₩1.82 Billion
≈ $1.24 Million
₩28.46 Billion
≈ $19.29 Million
-0.39pp
2023-12-31 6.80% ₩2.13 Billion
≈ $1.44 Million
₩31.35 Billion
≈ $21.25 Million
-8.23pp
2022-12-31 15.03% ₩4.79 Billion
≈ $3.25 Million
₩31.90 Billion
≈ $21.62 Million
-16.53pp
2021-12-31 31.55% ₩12.47 Billion
≈ $8.45 Million
₩39.53 Billion
≈ $26.79 Million
-0.42pp
2020-12-31 31.97% ₩12.20 Billion
≈ $8.27 Million
₩38.17 Billion
≈ $25.87 Million
+0.43pp
2019-12-31 31.54% ₩8.97 Billion
≈ $6.08 Million
₩28.46 Billion
≈ $19.28 Million
-16.84pp
2018-12-31 48.38% ₩15.25 Billion
≈ $10.33 Million
₩31.52 Billion
≈ $21.36 Million
+5.25pp
2017-12-31 43.13% ₩7.65 Billion
≈ $5.19 Million
₩17.74 Billion
≈ $12.02 Million
-6.16pp
2016-12-31 49.29% ₩9.53 Billion
≈ $6.46 Million
₩19.33 Billion
≈ $13.10 Million
+18.97pp
2015-12-31 30.31% ₩6.30 Billion
≈ $4.27 Million
₩20.78 Billion
≈ $14.08 Million
+8.02pp
2014-12-31 22.30% ₩3.80 Billion
≈ $2.58 Million
₩17.05 Billion
≈ $11.55 Million
+3.29pp
2013-12-31 19.00% ₩3.74 Billion
≈ $2.53 Million
₩19.68 Billion
≈ $13.33 Million
+1.01pp
2012-12-31 18.00% ₩3.66 Billion
≈ $2.48 Million
₩20.35 Billion
≈ $13.79 Million
+1.73pp
2011-12-31 16.27% ₩3.68 Billion
≈ $2.49 Million
₩22.62 Billion
≈ $15.33 Million
--
pp = percentage points

About GeneMatrix Inc

KQ:109820 Korea Diagnostics & Research
Market Cap
$18.97 Million
₩27.99 Billion KRW
Market Cap Rank
#25249 Global
#1841 in Korea
Share Price
₩1402.00
Change (1 day)
+1.52%
52-Week Range
₩1329.00 - ₩3245.00
All Time High
₩33900.00
About

GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also … Read more